Avidity Biosciences Inc. (NASDAQ: RNA) received breakthrough therapy designation from the U.S. Food and Drug Administration for delpacibart zotadirsen (del-zota) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE